JPRN-UMIN000010160已完成未知
Phase II trial as new chemotherapy regimen for bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancer. - Phase II trial as new chemotherapy regimen for bevacizumab (Bev) in combination with XELOX
Tsukasa Hotta0 个研究点目标入组 27 人开始时间: 2013年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Treatment for ascites and thoracic effusion is needed. 2.There is brain tumor or brain metastasis. 3.Untreated double cancer within 5 years 4.There is cerebrovascular disease 5.surgery within 4 weeks 6.surgery for study 7.use of drug effected for blood coagulation system 8.Bleeding tendency 9.Uncontrorable peptic ulcer 10.gastrointestinal perforation within 6 months 11.untreated fructure 12.renal failure 13.Uncontrorable hypertension 14.Uncontrorable diabetes meritus 15.heart disease 16.hypersensitivity for fluorouracil and platinum 17.DPD defect 18.Uncontrorable diarrhea 19.interstitial pneumonia or pulmonary fibrosis 20.organ transplant needed immunosuppressant drug 21.Uncontrorable infectious disease 22.similarterm for BV treatment 23.difficult for oral intake
研究者
相似试验
已完成
不适用
Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.StageII(high risk) and stageIIIa resectable colorectal cancerJPRN-UMIN000012813Tsukasa Hotta25
已完成
2 期
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patientsCD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000008024Kyoto University Hematology Study Group45
已完成
2 期
Phase II trial of neoadjuvant chemotherapy with Bevacizumab plus FOLFOX6 chemotherapy for Resectable case of liver metastasisJPRN-UMIN000001568Miyagi HBPCOG45
已完成
1 期
Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.Colorectal cancerJPRN-UMIN000009362ational Cancer Center Hospital, Tokyo, Japan.12
进行中（未招募）
不适用
Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct - TUD-Glivec-012advanced carcinoma of the gallbladder and bile ductEUCTR2006-003451-20-DETechnical University Dresden44